{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:20:43Z","timestamp":1793424043777,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jchromb.2021.123075","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T12:06:19Z","timestamp":1638360379000},"page":"123075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS\/MS"],"prefix":"10.1016","volume":"1188","author":[{"given":"Mirjana","family":"Radovanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Shafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2021.123075_b0005","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.jchromb.2021.123075_b0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_6-20","article-title":"Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?","volume":"7","author":"Seidman","year":"2002","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"10.1016\/j.jchromb.2021.123075_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000055264","article-title":"Xeloda in the treatment of metastatic breast cancer","volume":"57","author":"Blum","year":"1999","journal-title":"Oncology"},{"issue":"15_suppl","key":"10.1016\/j.jchromb.2021.123075_b0020","doi-asserted-by":"crossref","first-page":"e12566","DOI":"10.1200\/JCO.2017.35.15_suppl.e12566","article-title":"Long-term disease control with capecitabine in advanced breast cancer","volume":"35","author":"Masci","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2021.123075_b0025","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","volume":"14","author":"Wong","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2021.123075_b0030","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jchromb.2021.123075_b0035","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0305-7372(10)70020-7","article-title":"Update on capecitabine alone and in combination regimens in colorectal cancer patients","volume":"36","author":"Silvestris","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.jchromb.2021.123075_b0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jgh.13845","article-title":"Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.jchromb.2021.123075_b0045","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3390\/molecules13081897","article-title":"Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review","volume":"13","author":"Koukourakis","year":"2008","journal-title":"Molecules"},{"key":"10.1016\/j.jchromb.2021.123075_b0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jchromb.2021.123075_b0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/jco.2012.30.4_suppl.579","article-title":"BSA dosing and suboptimal 5-FU exposure among colorectal cancer patients of varying gender and age","volume":"30","author":"Haregewoin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2021.123075_b0060","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jchromb.2021.123075_b0065","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jchromb.2021.123075_b0070","first-page":"2039","article-title":"Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas","volume":"4","author":"Fety","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jchromb.2021.123075_b0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1365-2125.2003.01765.x","article-title":"Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients","volume":"55","author":"Gieschke","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jchromb.2021.123075_b0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bcp.14723","article-title":"Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine","volume":"87","author":"Schneider","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2021.123075_b0085","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1158\/1538-7445.AM2017-5042","article-title":"Abstract 5042: Defining an optimal single time point sampling strategy representative of overall capecitabine pharmacokinetics","volume":"77","author":"Welch","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jchromb.2021.123075_b0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical Pharmacokinetics of Capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2021.123075_b0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4155\/bio.14.310","article-title":"A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit","volume":"7","author":"Spooner","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2021.123075_b0100","unstructured":"NATA, General Accreditation Guidance \u2014Validation and verification of quantitative and qualitative test methods, DOI (2018)."},{"key":"10.1016\/j.jchromb.2021.123075_b0105","unstructured":"FDA, Guidance for Industry: Bioanalytical Methods Validation, DOI (2018)."},{"key":"10.1016\/j.jchromb.2021.123075_b0110","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC\u2212MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221005560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221005560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:06:33Z","timestamp":1761606393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023221005560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":22,"alternative-id":["S1570023221005560"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.123075","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.123075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123075"}}